These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 23266260)

  • 1. Relapse of tuberculosis versus primary tuberculosis; course, pathogenesis and therapy in mice.
    de Steenwinkel JE; de Knegt GJ; ten Kate MT; Verbrugh HA; Hernandez-Pando R; Leenen PJ; Bakker-Woudenberg IA
    Tuberculosis (Edinb); 2013 Mar; 93(2):213-21. PubMed ID: 23266260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Course of murine tuberculosis and response to first-line therapy depends on route of infection and inoculum size.
    de Steenwinkel JE; ten Kate MT; de Knegt GJ; Verbrugh HA; van Belkum A; Hernandez-Pando R; Bakker-Woudenberg IA
    Int J Tuberc Lung Dis; 2011 Nov; 15(11):1478-84, i. PubMed ID: 22008760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A preliminary study on immune adjunctive therapy for multidrug-resistant Mycobacterium tuberculosis infection in animal models].
    Hou JH; Li Q; Lu Y; Zheng MQ; Zhao WJ; Xu J
    Zhonghua Jie He He Hu Xi Za Zhi; 2012 Dec; 35(12):911-4. PubMed ID: 23328182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunological parameters to define infection progression and therapy response in a well-defined tuberculosis model in mice.
    De Steenwinkel JE; De Knegt GJ; Ten Kate MT; Van Belkum A; Verbrugh HA; Hernandez-Pando R; Van Soolingen D; Bakker-Woudenberg IA
    Int J Immunopathol Pharmacol; 2009; 22(3):723-34. PubMed ID: 19822089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct comparison of low-dose and Cornell-like models of chronic and reactivation tuberculosis in genetically susceptible I/St and resistant B6 mice.
    Radaeva TV; Nikonenko BV; Mischenko VV; Averbakh MM; Apt AS
    Tuberculosis (Edinb); 2005; 85(1-2):65-72. PubMed ID: 15687029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abatacept treatment does not exacerbate chronic Mycobacterium tuberculosis infection in mice.
    Bigbee CL; Gonchoroff DG; Vratsanos G; Nadler SG; Haggerty HG; Flynn JL
    Arthritis Rheum; 2007 Aug; 56(8):2557-65. PubMed ID: 17665452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting results of mycobacterial culture on sputum smear reversion after anti-tuberculous treatment: a case control study.
    Shu CC; Wang JT; Lee CH; Wang JY; Lee LN; Yu CJ
    BMC Infect Dis; 2010 Mar; 10():48. PubMed ID: 20205743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incorporation of immunostimulatory motifs in the transcribed region of a plasmid DNA vaccine enhances Th1 immune responses and therapeutic effect against Mycobacterium tuberculosis in mice.
    Wu J; Ma H; Qu Q; Zhou WJ; Luo YP; Thangaraj H; Lowrie DB; Fan XY
    Vaccine; 2011 Oct; 29(44):7624-30. PubMed ID: 21856352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polarization of PPD-specific T-cell response of patients with tuberculosis from Th0 to Th1 profile after successful antimycobacterial therapy or in vitro conditioning with interferon-alpha or interleukin-12.
    Marchant A; Amedei A; Azzurri A; Vekemans J; Benagiano M; Tamburini C; Lienhardt C; Corrah T; McAdam KP; Romagnani S; D'Elios MM; Del Prete G
    Am J Respir Cell Mol Biol; 2001 Feb; 24(2):187-94. PubMed ID: 11159053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Therapeutic effect of interleukin-12 on murine infection with Mycobacterium tuberculosis through modulating Th1 and Th2 cytokine balance].
    Zhang T; Kawakami K; Tang Y
    Zhonghua Jie He He Hu Xi Za Zhi; 2000 Jun; 23(6):358-60. PubMed ID: 11778519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of murine models of latent tuberculosis infection.
    Shi C; Shi J; Xu Z
    Scand J Infect Dis; 2011 Dec; 43(11-12):848-56. PubMed ID: 21892898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis.
    Ibrahim M; Truffot-Pernot C; Andries K; Jarlier V; Veziris N
    Am J Respir Crit Care Med; 2009 Sep; 180(6):553-7. PubMed ID: 19590024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Tuberculosis in compromised hosts].
    Kekkaku; 2003 Nov; 78(11):717-22. PubMed ID: 14672050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased IgG1, IFN-gamma, TNF-alpha and IL-6 responses to Mycobacterium tuberculosis antigens in patients with tuberculosis are lower after chemotherapy.
    Mattos AM; Almeida Cde S; Franken KL; Alves CC; Abramo C; de Souza MA; L'Hotellier M; Alves MJ; Ferreira AP; Oliveira SC; Ottenhoff TH; Teixeira HC
    Int Immunol; 2010 Sep; 22(9):775-82. PubMed ID: 20624776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and therapeutic effects of Ag85A/B chimeric DNA vaccine in mice infected with Mycobacterium tuberculosis.
    Liang Y; Wu X; Zhang J; Xiao L; Yang Y; Bai X; Yu Q; Li Z; Bi L; Li N; Wu X
    FEMS Immunol Med Microbiol; 2012 Dec; 66(3):419-26. PubMed ID: 23163873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Frontier of mycobacterium research--host vs. mycobacterium].
    Okada M; Shirakawa T
    Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lower expression of Th1-related cytokines and inducible nitric oxide synthase in mice with streptozotocin-induced diabetes mellitus infected with Mycobacterium tuberculosis.
    Yamashiro S; Kawakami K; Uezu K; Kinjo T; Miyagi K; Nakamura K; Saito A
    Clin Exp Immunol; 2005 Jan; 139(1):57-64. PubMed ID: 15606614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration.
    Lounis N; Veziris N; Chauffour A; Truffot-Pernot C; Andries K; Jarlier V
    Antimicrob Agents Chemother; 2006 Nov; 50(11):3543-7. PubMed ID: 16954317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.